Advanced Inflammatory Bowel Disease Fellow @ Mayo Clinic, Florida

Florida, USA
Passisd Laoveeravat retweeted
IBD Innovate offers a look at the IBD pipeline from early-stage concepts to near-market products. Connect with teams translating research into therapies, diagnostics, and devices that improve life for people with IBD. bit.ly/4h37hNO
2
2
404
Passisd Laoveeravat retweeted
💫Loved this analogy. As an IBD physician and the parent of a chess ♟️enthusiast, it resonated with me. 🎯Every move brings us one step closer to checkmating IBD. @ibdseb @P_DeepakIBDMD @drvishal82 @IBDimmunology ….
"Every IBD drug is a chess piece; victory belongs to the clinician who knows when to move it"
4
13
1,210
Passisd Laoveeravat retweeted
🇹🇭 APAGE–JGHF Young Clinicians' Programme & Inaugural GI Pathology Workshop | Bangkok, 15 July 2026 A wonderful start to the week in Bangkok, ahead of the 7th APAGE Clinical Forum on IBD (16–17 July). Today's pre-forum day brought together two important initiatives: 🩺 The APAGE–JGHF Young Clinicians' Programme, now in its third edition, equipping early-career gastroenterologists across Asia-Pacific with practical research skills, from framing a research question to getting published. Watching the next generation engage so actively with mentors from across the region is what this partnership is all about. 🔬The inaugural GI Pathology Workshop — a first for the APAGE IBD Forum, focusing on the interpretation and standardised reporting of mucosal biopsies in IBD and celiac disease. Histology remains one of the pillars of accurate IBD diagnosis, and closer dialogue between gastroenterologists and pathologists can only strengthen the care we deliver.
1
6
571
Passisd Laoveeravat retweeted
This was a nice case where the endoloop failed to detach, leaving the colonoscope-endoloop-polyp all stuck inside together. Endoloop is SUPER effective & every tool user should be comfortable troubleshooting the tool they use #Endoscopy #GITwitter #MedTwitter #MedEd
3
12
70
18,655
Passisd Laoveeravat retweeted
@vandana_midha with a clear and practical talk on where diet and dietary therapies sit in an Indian 🇮🇳 #IBD perspective There are some great studies and ongoing work from India in this space We need to adapt studies and recommendations to individual countries - apply the science to regional context This slide also drew my attention - EEN increased infliximab levels 🤔
2
8
18
4,110
Passisd Laoveeravat retweeted
Replying to @dr_singh_gastro
@dr_singh_gastro with a masterclass on the #Tb vs #IBD conundrum Some practical pearls and glimpse into future potential tools
5
15
631
It has been a very wonderful year to train with @ibdgijami on evidence based IBD and IUS training. Enjoy working at @MayoClinicFLGIH everyday. Thank you @ibdgijami
We are so proud of @passisd who completed his #IBD fellowship at @MayoClinicFLGIH 2025-2026 He is back off to Thialand where he will bring #IUS #IBD expertise @iUSCAN @BowelUltrasound It’s not goodbye it’s see you later! @FarrayeIBD @JHashashMD @JGubatanMD
1
1
19
3,152
Passisd Laoveeravat retweeted
BSG EndoBridge Series (7/15): Neoplasia in Inflammatory Bowel Disease Special Edition - open access for 6 months fg.bmj.com/content/17/e1/e72
3
6
1,850
Join us for the Mayo Clinic Gastroenterology & Hepatology Presentation Series Hosted by @MayoClinicFLGIH @MayoClinicGIHep @andree_koop will be moderating bite-sized educational sessions that will bring you up to date in #intestinalfailure #EGID #EoE #IBD #microbiome 🗓️ August 12 5:30-630PM EST (series will be quarterly) Register to save your spot tinyurl.com/3p6pzw3h
6
9
1,098
Avoidant/Restrictive Eating in People With and Without Bowel Symptoms in the General Population: Prevalence, Clinical Profile, and Associated Factors Blomsten, et al. 📕
1
7
12
1,909
Passisd Laoveeravat retweeted
The Twitterless Prof Sid Singh discussing medical therapy of fistulizing Crohn’s disease #SidSingh #AOCC2026 @MayoClinicGIHep Define, drainage, antibiotics, medical therapy. Use TOpClass for characterizing fistula
1
17
34
2,650
Passisd Laoveeravat retweeted
Starting off the inaugural AOCC–IBUS Advanced Module 3 in Seoul! 🇰🇷 Great to reconnect with friends and colleagues from across the IUS community, and an honour to present "What's New in IUS in UC." Exciting times for intestinal ultrasound in Asia. Wonderful faculty: Kayal Vizhi Nagarajan (India), Yoon-kyo An (Australia), Joyce Wing Yan Mak (Hong Kong), Kerri Novak (Canada), Sung Wook Hwang (Korea), Shintaro Sagami (Japan), Ryan Mathias (Australia) & Mariangela Allocca (Italy). Congratulations for the wonderful meeting. #AOCC2026 #ASIUS #bowelultrasonography @BowelUltrasound
2
10
464
Passisd Laoveeravat retweeted
While many advanced therapies can induce response in UC, upadacitinib gets you there faster. Our recent article published in @AGA_CGH compares onset of efficacy of biologic and small molecules in bio-naive UC. doi.org/10.1016/j.cgh.2026.0…
2
13
43
4,385
Passisd Laoveeravat retweeted
Interested in Global 🌎 #IBD We have a FREE in-person ( for 🇬🇧 HCPs) and online #IBD educational event at Hull on 20th &21st July 🌟Stellar Faculty 🌟Practical #IBD care tips 🌟Hot topics in #IBD 🌟Great debates Do register free. ibdconclave.viewcast.live
1
15
20
1,273
Passisd Laoveeravat retweeted
This feels like one of those rare moments that will be remembered for years. A historic achievement in oncology. 🎗👌 Thank you for sharing @marklewismd
Cheers, chills, and a standing ovation when RASolute 302 showed unprecedented survival on daraxonrasib for patients with progressive pancreatic cancer Seldom do you sense you’re witnessing a historic moment in cancer care but this feels like ras targeting has arrived #ASCO26
1
3
323
Passisd Laoveeravat retweeted
Tested out in #IBD clinic today. Saw pt with IBD-PSC. Asked when next colonoscopy should be and @openevidence did not detect that he had PSC
Cedars Sinai clinicians are the FIRST to use OpenEvidence to integrate live patient context from Epic and access personalized CDS AI. My 6 thoughts on what this means for the industry: First, the gist of what was announced: → Clinicians can ask questions in natural language and receive answers grounded in both research guidelines AND the specific patient in front of them (the holy grail of CDS AI!) → Patient context includes prior procedures, comorbidities, medications, allergies, and longitudinal health data - not just a summary snapshot → The system operates agentically: it interprets the clinical question, dynamically pulls relevant EHR data, evaluates current literature, and synthesizes a context-aware answer → Cedars-Sinai is also going to display its own protocols and guidelines alongside the medical literature, so clinicians can see both Alright my 6 thoughts: 1/ This reduces the friction to clinicians at Cedars Sinai trying OE. If you were using one of the other CDS AI tools before, you’d be hard pressed to now. You just save so much more time. 2/ It’s inevitable that Epic will just build the same integration with OE, UpToDate, Doximity and others directly into the chat bar interface (new Epic Toolbox category soon?) - where clinicians already do all their other actions with Epics AI clinician assistant “Art”. The pitch from Epic will be “why would you want to open up a separate tab every time you want to ask an AI assistant to do something?” - and they’d be right. When the output from the CDS AI is mostly plain text, it’s not so important for the CDS AI to own the UI/UX. 3/ But if this happens, then the CDS AI tools will be no different than the AI model products in general (ie OpenAI, Anthropic) - Epic will just let health systems switch them in and out. Oh, and of course, the CDS AI tools will pay the Epic App Store fee for this. 4/ Which means if you are a CDS AI tool and you want doctors to stay in your window, you have to offer something useful beyond a chat interface. Then again, if you’re getting faster distribution because Epic facilitates more native integrations with your CDS AI model - do you care to own the UI/UX? 5/ If you’re OE, Doximity, UpToDate - your goal should be to do as many of these EHR integrations as possible to prove you are the CDS AI model of choice. Put yourself in pole position for Epic to make you their default CDS AI model and be willing longterm to give up ownership of the UI/UX to Epic - because, well, they already own it. 6/ What does this mean for the AI scribe tools like Abridge that incorporated CDS into their product? Maybe they need to make CDS AI also available outside the live clinical encounter and become the default instead of OE - because won’t physicians want to use the same CDS AI during the encounter that they use outside of it (or do they not care)? But none of this matters if health systems choose to make Epic the interface for all this.
6
3
12
2,806
Passisd Laoveeravat retweeted
#IBDAlgorithm 🧬VEO-IBD 💭Think monogenic disease, esp. 🦠Recurrent infections 🍑Severe perianal Dx. 🚩 Growth failure 🧪 Genetic testing guides precision therapy & identify HSCT candidates early. 🎯 Diagnose first, then treat. 🗳️PostConvo polls👇(Answers in #IBDAlgo😉)
1
22
37
2,134